Alzheimer's disease is a progressive brain disorder that slowly destroys memory, thinking skills, and eventually the ability to carry out the simplest tasks. It is the most common cause of dementia in older adults.
A Cochrane review of 17 trials finds amyloid-beta-targeted monoclonal antibodies offer negligible benefit in MCI or mild Alzheimer’s. In a phase 3 trial, the oral agent valiltramiprosate (ALZ-801) showed significant cognitive and functional improvements in the MCI subgroup, with no brain swelling risk. The company plans another phase 3 study in 2026.
Researchers have developed an integrated live-cell imaging and cytometry workflow to monitor brain organoid differentiation. Separately, experiments on the International Space Station show that microgravity accelerates organoid aging by roughly a decade in 30 days, offering a faster model for neurodegenerative diseases. These advances could enhance drug discovery and neurodevelopmental research.
Anthropic announced it will run its own preclinical drug-discovery programs for neglected and rare diseases and launched Claude Science, an AI workbench for researchers. The company has not named specific diseases or detailed how it would bring candidates to market.
The UK's £1.6bn national AI strategy targets healthcare breakthroughs from cancer detection to drug discovery. The AI healthcare market is forecast to reach US$696bn by 2034, a 38.5% CAGR.
Yale researchers built genomic AI models for personalized medicine. The University of Liverpool and BPGbio will expand AI drug discovery via the NAi platform.
Alzheimer's blood tests are gaining FDA clearances and strong patient interest, yet surveys show clinicians remain skeptical about their reliability and clinical benefit. A UK survey found fewer than one-third of psychiatrists have used biomarkers, while only 6% of memory services meet access guidelines. An ethical framework urges careful implementation, especially in primary care.
UC San Diego is using space-based research to fight cancer and Alzheimer's, including the longest-running biologic experiments in space. A 2024 World Economic Forum report forecasts the space economy reaching $1.8 trillion by 2035.
Two studies identify protein recycling dysfunction and transcription factors ZSCAN20/JDP2 as drivers of T-cell exhaustion, with E3 ligases and gene deactivation offering reversal pathways. A third study finds TCF1 insufficient to revert terminally exhausted T cells.
Roche's Elecsys pTau181 test received FDA clearance for primary care use, and its Elecsys ApoE4 test earned CE Mark approval. Despite these advances, Medicare does not cover Alzheimer's blood biomarker screenings before symptoms appear, prompting the bipartisan ASAP Act.
GLP-1 drugs are still being studied for Alzheimer’s and addiction after semaglutide failed to slow cognitive decline in Alzheimer’s. A 2025 abstract reported semaglutide slowed cognitive impairment in an Alzheimer’s model.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07708675 |
Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease - EU |
NOT_YET_RECRUITING | NA |
| NCT05655195 |
Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy |
RECRUITING | NA |
| NCT03090516 |
Clinical Efficacy of Ginkgo Biloba Extract in the Treatment of Alzheimer's Disease |
UNKNOWN | PHASE2/PHASE3 |
| NCT00209456 |
Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia |
COMPLETED | PHASE3 |
